SBIR/STTR Research Award
Effect of VBP15, a dissociative steroidal analogue, on intestinal epithelial repair processes in inflammatory bowel disease
Award amount
$225,000Program and phase
STTR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- REVERAGEN BIOPHARMA, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- NQA4J3L3E1Z4
- Solicitation number
- PA14-072
- Topic code
- NIDDK
Research abstract
? DESCRIPTION (provided by applicant): Glucocorticoids (e.g. prednisolone) are prescribed frequently to treat inflammatory bowel disease (IBD). Despite effectiveness, adverse side effects believed to be caused by GRE-mediated transcriptional propertieslimit long term use of glucocorticoids in IBD patients. Furthermore, these GRE-mediated transcriptional activities have been previously shown to be responsible for glucocorticoid-induced impaired healing of the intestinal epithelium. This may explain whyglucocorticoids do not appear to be effective in maintaining remission of disease. ReveraGen BioPharma has identified a novel dissociative steroidal compound (VBP15) designed that retains the anti-inflammatory efficacy of traditional steroids (via NFkB inhibition), but has lost GRE-mediated transcriptional activities. VBP15 treatment has been shown to reduce inflammatory activity in vivo in multiple models of disease including the TNBS-induced mouse model of colitis (preliminary data) and result in a much m
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales
- Pivotal trial of vamorolone in Duchenne muscular dystrophy
- Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth
- Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials
- Establishing a biomarker framework for feasibility studies of vamorolone in vasculitis
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
11 SBIR/STTR records share this UEI (2010–2020). Reported award amounts total $11,189,078. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services